GN41851: A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis. See Fenebrutinib Website.

April 07, 2021
https://clinicaltrials.gov/ct2/show/NCT04586010
Neurology
Principal Investigator: Mirela Cerghet, MD
Multiple Sclerosis, Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
Open
313-916-1482